Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis
This study reveals a trend toward increasing FLT3-TKI use and highlights the need for repeated FLT3 testing among R/R AML patients. Real-world evidence is vital in understanding R/R AML patient care amidst emerging therapies. .
Authors
- Alana Block
- David L. Grinblatt (ORCID: https://orcid.org/0000-0002-2118-0042)
- Ziyu Lan
- Mark S. Walker (ORCID: https://orcid.org/0000-0002-3276-2689)
- Amer Methqal Zeidan (ORCID: https://orcid.org/0000-0001-7017-8160)
- Dina Elsouda
- Maelys Touya
- Yuexi Wang (ORCID: https://orcid.org/0000-0003-1749-0520)
- Bhavik J. Pandya
- James Spalding
- Rebekah Yu
Institutions
- Concern Worldwide US (US)
- Yale Cancer Center (US)
- Evanston Hospital (US)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1159/000545384
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders